Latest breakthroughs in cancer research, treatment, and prevention
598 articles
Tumor-infiltrating adipocytes release a lipid metabolite that triggers neutrophil cell death, suppressing CD8+ T cells in pancreatic cancer.
A Nature Medicine study finds pathogenic germline variants in pediatric patients signal elevated cancer risk, reshaping early genetic screening protocols.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
Circulating tumor DNA testing alongside primary treatment may sharpen prognosis for men with metastatic prostate cancer.
CRC cells exploit a heme-SDH-CoQ axis to neutralize iron-induced oxidative stress, revealing new therapeutic targets.
A pilot trial tested a comprehensive physical, mental, and spiritual intervention for cancer survivors, tracking outcomes at 6 months post-program.
Nivolumab plus standard chemotherapy receives FDA approval for classical Hodgkin lymphoma, expanding immunotherapy's role in blood cancers.
MSK-led research drove 10 FDA cancer drug approvals in 2025, including nivolumab combined with chemotherapy for classical Hodgkin lymphoma.
Nivolumab added to standard chemotherapy wins FDA approval, offering a new frontline option for classical Hodgkin lymphoma patients.
